Leaving the EU Negotiations continue to determine the UK’s new relationship with the EU. We are working to ensure that the voice of the medical research charity sector is heard as part of the process. No negative impact on patients Our member charities agree that it’s vital for the deal reached to ensure there is no negative impact on patients. This applies both within the UK and across the EU. This means patients must be able to continue to: Participate in vital pan-EU clinical trials Have speedy access to new medical innovations Experience no disruption in the supply of medicines and treatments Benefit from the fruits of innovative research collaborations across the UK and EU [read this report about the importance of international collaboration] We are working with key stakeholders to ensure: The UK is positioned as an attractive destination for global research talent and expertise An aligned and compatible regulatory framework is implemented between the UK and the EU for medical research The European Medicines Agency on EU regulatory frameworks and agreements for medicines and medical devices confirms patients will have timely access to new health innovations Continued participation in EU funding programmes and collaborative opportunities to progress the discovery and understanding of disease and ill health. No disruptions to the supply and trade of medicine and other health technologies from day on of the UK’s new relationship with the EU. Brexit Health Alliance We’re a member of the Brexit Health Alliance, which brings together the NHS, medical research, industry, patients and public health organisations to safeguard the interests of patients, and the healthcare and research they rely on during the Brexit negotiations. We’ve published several position statements and consultations responses related to leaving the EU.